21 November 2024
DEP SN38 Results Showcased at GI Cancer Conference
6 November 2024
Appendix 3Y
1 November 2024
Appendix 3G
31 October 2024
Quarterly Activities Report & Appendix 4C
29 October 2024
Australian Microcap Conference Presentation
28 October 2024
Notice of Annual General Meeting/Proxy Form
25 October 2024
Appendix 2A
24 October 2024
Appendix 3Y
18 October 2024
SPL7013 Nasal Spray Australia Update
3 October 2024
Appendix 3H
3 October 2024
Date of Annual General Meeting 2024
16 September 2024
Appendix 3Y
12 September 2024
Starpharma Receives $5.5M R&D Tax Incentive Refund
9 September 2024
Ceasing to be a substantial holder
2 September 2024
Appendix 3Y
2 September 2024
Appendix 3Y
28 August 2024
Appendix 2A
27 August 2024
Change in Substantial Holding
22 August 2024
Starpharma Annual Report and Full-Year Financial Results
30 July 2024
Quarterly Activities Report & Appendix 4C

Investor Relations

For general questions about Starpharma Holdings Limited, please contact us at:

T: +61 3 8532 2700
E: investor.relations@starpharma.com

Important Notice

This website is intended for people seeking information about Starpharma for investment and business purposes. This website contains information about products that may not be available, or approved, in all countries, or may be available under different trademarks, or for different indications. Individuals seeking information about a Starpharma product should visit the relevant product website in their country of residence or consult a healthcare provider. Nothing contained on this site should be considered a solicitation, promotion, or advertisement for any product, including those under development. Any information on this site is not intended to provide medical advice nor should be used as a substitute for the advice provided by a doctor or other healthcare provider.